세계의 핵의학용 방사성동위원소 시장 : 제품, 용도, 최종사용자, 지역별(2025-2033년)

The global nuclear medicine radioisotopes market size reached USD 7.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.0 Billion by 2033, exhibiting a growth rate (CAGR) of 7.13% during 2025-2033. The rising prevalence of cancer, the escalating demand for nuclear medicines, and various technological advancements represent some of the key factors driving the market.

Nuclear medicine radioisotopes are radioactive substances that are used in diagnostic and therapeutic procedures for various medical conditions. These radioisotopes emit radiation, which can be detected and measured to provide information about the structure and function of organs and tissues in the body. They are mainly utilized for diagnostic and therapeutic applications. In diagnostic applications, radioisotopes are employed to create images of the body's internal organs and systems. This allows healthcare professionals to identify abnormalities and diagnose conditions such as cancer, heart disease, and neurological disorders. On the other hand, in therapeutic applications, radioisotopes are used to deliver targeted radiation therapy to cancer cells or other abnormal tissues in the body. Moreover, nuclear medicine radioisotopes have several advantages over traditional diagnostic and therapeutic procedures as they are non-invasive, do not require surgical incisions or other invasive procedures, and have a lower risk of side effects and complications compared to treatments such as chemotherapy or radiation therapy. Owing to these benefits, nuclear medicine radioisotopes are widely utilized in hospitals across the globe.

Nuclear Medicine Radioisotopes Market Trends:

The market is primarily driven by the growing prevalence of cancer among individuals. Nuclear medicine radioisotopes are widely used in cancer diagnosis solutions such as PET scans and treatment therapies. In addition, the rising geriatric population that is more susceptible to chronic diseases such as cancer, heart disease, and neurological disorders, which require the use of nuclear medicine radioisotopes, represents another major growth-inducing factor. Besides this, various technological advancements have led to the development of new and improved diagnostic and therapeutic applications of nuclear medicine radioisotopes. This, coupled with the increasing investment and demand for nuclear medicines, is positively influencing market growth. Governments and private organizations are investing heavily in the research and development of nuclear medicine technologies, leading to the creation of new products and applications, which in turn is driving the market growth. Moreover, the market is also propelled by the growing patient awareness about radiation and radiation therapy. Furthermore, the rising healthcare expenditure, the launch of advanced product variants, and increasing research and development activities conducted by key players are other factors creating a favorable market outlook.

Key Market Segmentation:

Product Insights:

• Diagnostics
• Technetium-99m (Tc-99m)
• Gallium-67
• Thallium-201
• Fluorine-18
• Others
• Therapeutics
• Rhenium-186
• Iodine-131
• Samarium-153
• Yttrium-90
• Others

Application Insights:

• Cardiology
• Oncology
• Thyroid
• Neurology
• Others

End User Insights:

• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Education and Research Institutes
• Others

Regional Insights:

• North America
• United States
• Canada
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for nuclear medicine radioisotopes. Some of the factors driving the North America nuclear medicine radioisotopes market included aging population, technological advancements, rising prevalence of cancer.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global nuclear medicine radioisotopes market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bracco S.p.A., Bruce Power Inc., Cardinal Health Inc., China Isotope & Radiation Corporation (China National Nuclear Corporation), Curium Pharma, Eckert & Ziegler, Nordion (Canada) Inc (Sotera Health Company), NorthStar Medical Radioisotopes, LLC, NTP Radioisotopes SOC Ltd.,Shine Technologies LLC, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global nuclear medicine radioisotopes market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global nuclear medicine radioisotopes market?
• What is the impact of each driver, restraint, and opportunity on the global nuclear medicine radioisotopes market?
• What are the key regional markets?
• Which countries represent the most attractive nuclear medicine radioisotopes market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the nuclear medicine radioisotopes market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the nuclear medicine radioisotopes market?
• What is the breakup of the market based on end user?
• Which is the most attractive end user in the nuclear medicine radioisotopes market?
• What is the competitive structure of the global nuclear medicine radioisotopes market?
• Who are the key players/companies in the global nuclear medicine radioisotopes market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Nuclear Medicine Radioisotopes Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Diagnostics
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Technetium-99m (Tc-99m)
    • 6.1.2.2 Gallium-67
    • 6.1.2.3 Thallium-201
    • 6.1.2.4 Fluorine-18
    • 6.1.2.5 Others
  • 6.1.3 Market Forecast
• 6.2 Therapeutics
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Rhenium-186
    • 6.2.2.2 Iodine-131
    • 6.2.2.3 Samarium-153
    • 6.2.2.4 Yttrium-90
    • 6.2.2.5 Others
  • 6.2.3 Market Forecast

7 Market Breakup by Application

• 7.1 Cardiology
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Oncology
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Thyroid
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Neurology
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Diagnostic Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Specialty Clinics
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Education and Research Institutes
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Bracco S.p.A.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 SWOT Analysis
  • 14.3.2 Bruce Power Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 SWOT Analysis
  • 14.3.3 Cardinal Health Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 China Isotope & Radiation Corporation (China National Nuclear Corporation)
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Curium Pharma
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Eckert & Ziegler
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Nordion (Canada) Inc (Sotera Health Company)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 NorthStar Medical Radioisotopes, LLC
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 NTP Radioisotopes SOC Ltd
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Shine Technologies LLC
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.